Key Statistics for VPHM
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for VPHM
- Net Income (M/USD)
ViroPharma Incorporated is a biopharmaceutical company committed to the commercialization, development, and discovery of new medicines. The Company's products include a treatment for prophylaxis of hereditary angioedema as well a capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis.
More Company Profile & Key Executives for VPHM
|Vincent J Milano "Vin"Chairman/President/CEO||Charles A Rowland JrVP/CFO|
|Daniel B SolandVP/COO||Colin BroomVP/Chief Scientific Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.